Therapy starts remain stubbornly flat, despite dashboards highlighting spikes in ePA and digital tool usage. Brand teams are increasingly tasked with addressing the disconnect between download surges and the lack of corresponding filled prescriptions. Discovery, ePA, enrollment, and activation analytics represent four essential patient support steps, yet they are often siloed within their own dashboards and managed by different vendors, each focused on their own metrics. This fragmentation not only complicates operations but also conceals the true sources of value loss and patient abandonment. Isolated solutions cannot resolve these issues; every disconnected step introduces opportunities for drop-off, error, or mis-measurement. Manufacturers that transition from pursuing incremental funnel victories to establishing a seamless, integrated workflow within the EHR will achieve the outcomes that others continue to overlook.
Fragmentation in patient support program workflows creates unseen drop-off points across specialty therapy access. Brands routinely juggle separate vendors for discovery, electronic prior authorization (ePA), enrollment, and activation analytics—each reporting their funnel in isolation. Surescripts reported a 49% year-over-year increase in electronic prior authorizations processed in 2023 and accelerating growth in clinical messaging between prescribers, payers, and pharmacists (Surescripts, 2024). Yet, despite technology gains, most brand teams still manage four different funnels and never see where the real leak happens. The cost is measured in abandoned scripts, unconverted copay dollars, and missed therapy starts. Connected workflow—the ability to see, measure, and improve every handoff as one system—remains the unclaimed answer to specialty access fragmentation.
A few years ago, the model was simpler. Each critical step—discovery, ePA, enrollment, and activation—was managed by separate owners, each team focusing on its own metrics and vendors. The digital group or an outside partner ran discovery. Enrollment was handed to the hub. ePA became whichever system a health system picked. Activation analytics was often siloed on a dashboard far from the others.
Everyone justified this approach as modernization: more platforms meant plugging more workflow gaps. Each solution produced a metric that looked like progress for their corner—discovery went up, ePA cleared faster, AI made enrollment smoother. But this vendor-by-vendor focus always left a blind spot: the end-to-end impact. Fills lagged the dashboard wins. Therapy-start never caught up to shiny enrollment numbers. Commercial teams never had a direct line connecting spend with real-life therapy starts.
This segmented approach is the norm across US specialty brands. Vendor stacks are still built around dividing the patient-support journey, not unifying it. Surescripts reported a 49% boost in ePA volume and specialty medicines saw a 20% increase (Surescripts, 2024). Over 881,000 organizations now trade clinical messages, giving the impression of technical integration.
But national data highlights the core issue: adoption of digital tools alone does not bridge the real workflow gaps. Discovery and enrollment charts show flashes of progress, but actual fills stay stagnant. The risk compounds at each disconnect—between discovery, ePA, enrollment, and activation. Each system chases its metric, but the abandonment points stay hidden. A patient can finish discovery, get ePA, enroll, then still abandon at the pharmacy because the workflows never connect.
What looks like technological progress is actually deeper fragmentation. Last year, pharmacist-issued e-prescriptions jumped 13%, and pharmacist e-prescribing system use rose nearly 29% (Surescripts, 2024). These are indicators of growing digital capacity, but without holistic workflow design, the drop-off gaps persist.
The roots of fragmentation run deeper than legacy contracts or slow vendor onboarding. Each capability—discovery, ePA, enrollment, analytics—has matured into its own self-contained vendor category, each tuned to optimize its local role. Budgets, contracts, and operations reinforced these silos.
The outcome: brands pay for fragmented progress. Awareness, speed to payer, completed forms, or lagging analytics all show up as individual wins, but no vendor spans the whole journey. True drop-off analysis only comes after problems accumulate, when data lags and retroactive reporting hides the root cause.
These gaps are built in. Each vendor’s incentives encourage local maximization—an enrollment solution might tout stellar form completions, but has no visibility into whether fills improve. The industry keeps rewarding local progress and missing total-chain results.
Today’s stacks mirror these fragmentation patterns. Platforms for discovery focus on patient affordability but rarely connect to what happens down the line. ePA platforms showcase scale—Surescripts tracked a 122% jump in pharmacist participation since 2019 (Surescripts, 2024)—but don’t track affordability or enrollment status. Hubs chase completion metrics. Analytics tools measure what they can, but only inside their own data walls.
Manufacturer teams are left buying top tools for each slice. But as digital capability increases, so does system complexity: more vendors, contracts, handoffs, and duplicated onboarding.
Fragmentation creates friction that is felt as hidden operational costs: duplicated FTE labor, redundant portals, and dampened outcomes. By the time enrollment stalls or abandonment spikes, detection is retrospective—the handoff failure happened long ago, unmeasured in that moment.
Fragmentation bleeds value in invisible ways. Metrics for ePA and digital enrollment may rise, but therapy starts stubbornly resist change. A savings card can be downloaded, but sit unactivated behind a stuck prior auth. Forms are finished, but without the right benefit check, fills fall short. No amount of AI in just one workflow patch can undo an upstream process gap.
Data shows that more than 60% of patients drop off between discovery and completed enrollment (Asembia, 2024). Growth in direct clinical messaging—expanding to over 22,000 pharmacies last year (Surescripts, 2024)—marks progress, but not true workflow closure. These investments create technical connection, not operational continuity.
Brand directors face the reality: four separate, irreconcilable reports and an inability to tie spend to therapy starts. Launches may look solid on slides, but lose ground at launch or in the field. Internal reviews spiral into vendor-by-vendor defenses while fill rates stay flat.
Every specialty program, regardless of stack, faces the same three workflow breakpoints:
Each broken link amplifies loss—good metrics at isolated stages can’t prevent the overall journey from stalling if the steps do not fit together seamlessly.
When brands adopt new tech, hoping to patch gaps, the result is usually more tools layered on top of the old silos—not true workflow connection. E-prescribing, RTBC, AI forms, and clinical messaging all post impressive adoption statistics. Surescripts reports a nearly 29% bump in pharmacist e-prescribing and a 13% rise in pharmacist-issued scripts (Surescripts, 2024). But these only tell the story of digital enablement, not outcome connection.
Platforms integrate technically but fall short of operational integration. Reporting is often lagged, with attribution murky. None provide a continuous, transparent arc from intervention to the moment a patient begins therapy.
The tech stack keeps growing around point-specific product gaps, not the larger activation and workflow gaps. Progress at the feature level does not accrue to commercial targets until there is true workflow unification.
The real problem is not too little technology, but too little connection. Industry thinking defaults to “add a new tool, patch a workflow gap.” But every well-optimized function in isolation fuels the next bottleneck if activation and workflow gaps are left unaddressed. The heart of the matter: brand teams need to orchestrate one EHR-native flow where discovery, benefit check, prior auth, and enrollment are tied to therapy start—closing the activation gap, not just adding tools.
With a function-by-function mindset, every fix just shifts the break further down the chain. Capability in the absence of connection is never enough. The only way to actually close abandonment is to stop thinking about features and start building for end-to-end closure—each handoff, each metric, each workflow moment designed for continuity.
A major shift is underway: success is being redefined not by the depth of individual features, but by the degree of workflow connectivity.
With this connected approach, every step moves together: discovery turns into real-time support surfaced in the EHR, ePA triggers before a prescription leaves the workflow, enrollment and activation are tied directly to therapy-start, and analytics become actionable.
Point platforms have targeted pieces of this problem: ePA vendors have scaled approvals (Surescripts, 2024), hubs drive enrollment, DTC coupons give visibility, but none link the journey from initial discovery through to therapy start.
co-pay.com positions itself as the connective layer—joining co-pay discovery, RTBC at prescribing, ePA before pharmacy, AI-guided enrollment (screened from portal confusion), activation confirmation, and patient-level analytics within one EHR-native experience. This does not mean competing on discrete features. It means eliminating the gaps between fragments, so commercial teams finally see the tie between program spend and the one outcome that counts: therapy start.
Digital health’s story has too often been about new tools and incremental fixes, but commercial value comes when workflow and activation gaps close for good. Layering solutions without true integration increases fragmentation—a proliferation of dashboards and linked metrics, while actual fills stall. This is not a data visibility issue, but an architectural impasse.
The advantage now belongs to teams that recognize the need for connected, EHR-native activation and treat "activation gap" and "workflow gap" as central metrics. By unifying what was four separate, siloed workflows, brands finally anchor measurement not to upstream milestones, but to true therapy start. The future is owned by those ready to tie every digital investment and vendor metric directly to what matters: confirmed therapy start.
Fragmentation persists because each function—discovery, prior authorization, enrollment, activation—evolved as a separate vendor category, measured and improved as its own outcome. As commercial priorities shifted and access demands grew, brands adopted top-performing tools for each step, but rarely connected the full patient journey in one workflow. The result is four separate funnels, each performing well in isolation but leaking value at every handoff (Asembia, 2024).
The hidden costs include operational complexity, delayed script fills, redundant reporting, and missed therapy starts. Brands may see strong engagement in a discovery or enrollment program, but those wins often fail to translate to confirmed fills if other steps stall. Fragmented stacks increase the risk of abandonment during critical moments—when prior authorization is still pending, or when enrollment friction breaks the journey. The result: unconverted copay investment and missed commercial targets (Asembia, 2024).
Even as ePA volumes increase and digital messaging tools proliferate, specialty access remains fragmented because each new tool is typically layered on as a new contract and workflow. Technology upgrades at each point add speed and data, but the connection across the patient journey remains incomplete unless architected from the EHR out—discovery, RTBC, ePA, enrollment, and activation as one connected workflow (Surescripts, 2024).
There are three major breakpoints: discovery timing (did the patient or prescriber see the program inside the workflow), prior authorization pending (did PA clear before fill is attempted), and enrollment friction (did the patient make it through the enrollment without dropping off). Each is a statistical drop-off point according to analyst tracking (Asembia, 2024).
A connected workflow unifies all necessary functions—co-pay discovery, real-time benefit check, electronic prior authorization, AI-guided enrollment, activation confirmation, and patient-level analytics—into one EHR-native system. Rather than four vendors or portals, everything runs as a single process, tied to the same patient record and therapy-start endpoint (Surescripts, 2024).
Pharmacists have become increasingly involved in both e-prescribing and prior authorization workflows. Surescripts reported a 122% increase in pharmacists on its network between 2019 and 2022, and a 47% increase in pharmacist-issued e-prescriptions, signaling a growing role for pharmacists in managing access and clinical messaging. Their active participation can mitigate access delays, but only if workflows are truly connected (Surescripts, 2024).
Hub vendors bring value for enrollment and patient support services, but their architecture was never designed for in-EHR connection. Most operate downstream, only coming into play after the prescription is written and the patient leaves the clinical encounter. The future points to architectures that pilot alongside existing hubs, but connect discovery, ePA, enrollment, and activation inside the prescribing workflow, not after.
Brand teams can unify the funnel by insisting on EHR-native connected workflow as the standard—piloting platforms that combine discovery, RTBC, ePA, and AI enrollment in a single patient journey. This eliminates drop-off at handoffs, produces one source of data for therapy-start attribution, and allows every intervention to be measured by its real commercial impact. Operationalizing this approach often requires cross-team ownership and a willingness to rethink legacy vendor portfolios (Surescripts, 2024).
Yes. Fragmentation erodes pull-through and makes cost-per-therapy-start unmeasurable. As long as brand teams remain accountable for fulfillment but manage segmented access chains, commercial outcomes will lag. Eliminating fragmentation turns activation and engagement metrics into confirmed therapy starts, which is the only performance indicator that matters at the brand P&L level (Asembia, 2024).
Not always. Additional tools can help, but if each one is deployed as a stand-alone fix, they risk compounding fragmentation. The critical shift is moving from incremental capability improvement to architectural connection—making sure all access steps function as a unified EHR-native workflow.